Positron emission tomography in urological oncology

Journal of Urology

Volumn 159, Issue 2, 1998, Pages 347-356

  Hoh, Carl K ^a   Seltzer, Marc A ^a   Franklin, John ^a   DeKernion, Jean B ^a   Phelps, Michael E ^a   Belldegrun, Arie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Kidney neoplasms; Prostatic neoplasms; Testicular neoplasms; Tomography, emission computed

Indexed keywords

6 FLUORODOPA F 18; FLOXURIDINE; FLUORODEOXYGLUCOSE F 18; TRACER;

DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; IMAGE ANALYSIS; LYMPH NODE METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; URINARY TRACT CANCER;

EID: 0031985133     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63916-8     Document Type: Review

References (102)

1. Jones, S. C., Alavi, A., Christman, D., Montanez, I., Wolf, A. P. and Reivich, M.: The radiation dosimetry of 2 [F-18]fluoro-2-deoxy-D-glucose in man. J. Nucl. Med., 23: 613, 1982.
2. Joensuu, H. and Ahonen, A.: Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J. Nucl. Med., 28: 910, 1987.
3. Bloom, A. D., Adler, L. P. and Shuck, J. M.: Determination of malignancy of thyroid nodules with positron emission tomography. Surgery, 114: 728, 1993.
4. Sisson, J. C., Ackermann, R. J., Meyer, M. A. and Wahl, R. L.: Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J. Clin. Endo. Metab., 77: 1090, 1993.
5. Adler, L. P. and Bloom, A. D.: Positron emission tomography of thyroid masses. Thyroid, 3: 195, 1993.
6. Wahl, R. L., Cody, R. L., Hutchins, G. and Mudgett, E.: Positron-emission tomographic scanning of primary and metastatic breast cancer with the radiolabeled glucose analogue 2-deoxy-2-[18F]fluoro-D-glucose [letter]. N. Engl. J. Med., 324: 200, 1991.
7. Wahl, R. L., Cody, R. L., Hutchins, G. D. and Mudgett, E. E.: Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-Fluoro-2-deoxy-D-glucose. Radiology, 179: 765, 1991.
8. Tse, N. Y., Hoh, C. K., Hawkins, R. A., Zimmer, M. J., Dahlbom, M., Choi, Y., Maddahi, J., Brunicardi, F. C., Phelps, M. E. and Jaspy, J. A.: The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann. Surg., 216: 27, 1992.
9. Adler, L. P., Crowe, J. P., al-Kaisi, N. K. and Sunshine, J. L.: Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology, 187: 743, 1993.
10. Nieweg, O. E., Kim, E. E., Wong, W. H., Broussard, W. F., Singletary, S. E., Hortobagyi, G. V. and Tilbury, R. S.: Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. CA, 71: 3920, 1993.
11. Paul, R.: Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J. Nucl. Med., 28: 288, 1987.
12. Okada, J., Yoshikawa, K., Imazeki, K., Minoshima, S., Uno, K., Itami, J., Kuyama, J., Maruno, H. and Arimizu, N.: The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J. Nucl. Med., 32: 686, 1991.
13. Leskinen-Kallio, S., Ruotsalainen, U., Nagren, K., Teräs, M. and Joensuu, H.: Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J. Nucl. Med., 32: 1211, 1991.
14. Okada, J., Yoshikawa, K., Itami, M., Imaseki, K., Uno, K., Hami, J., Kuyama, J., Mikata, A. and Arimizu, N.: Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J. Nucl. Med., 33: 325, 1992.
15. Hoekstra, O. S., Ossenkoppele, G. J., Golding, R., Van Lingen, A., Visser, G. W., Teule, G. J. and Huijgens, P. C.: Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J. Nucl. Med., 34: 1706, 1993.
16. Newman, J. S., Francis, I. R., Kaminski, M. S. and Wahl, R. L.: Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology, 190: 111, 1994.
17. Hoh, C. K., Glaspy, J. A., Rosen, P. J., Dahlbom, M., Lee, S. J., Kunkel, L., Hawkins, R. A., Maddahi, J. and Phelps, M. E.: Whole body FDG PET imaging for staging of Hodgkin's disease and lymphoma. J. Nucl. Med., 38: 343, 1997.
18. Nolop, K. B., Rhodes, C. G., Brudin, L. H., Beaney, R. P., Krausz, T., Jones, T. and Hughes, J. M.: Glucose utilization in vivo by human pulmonary neoplasms. CA, 60: 2682, 1987.
19. Kubota, K., Matsuzawa, T., Fujiwara, T., Ito, M., Hatazawa, J., Ishimata, K., Imata, R. and Ido, T.: Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J. Nucl. Med., 31: 1927, 1990.
20. Gupta, N. C., Frank, A. R., Dewan, N. A., Redepenning, L. S., Rothberg, M. L., Mailliard, J. A., Phalen, J. J., Sunderland, J. J. and Frick, M. P.: Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology, 184: 441, 1992.
21. Patz, E. F., Jr., Lowe, V. J., Hoffman, J. M., Paine, S. S., Burrowes, P., Coleman, R. E. and Goodman, P. C.: Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology, 188: 487, 1993.
22. Hunter, G. J., Choi, N. C., McLoud, T. C. and Fischman, A. J.: Lung tumor metastasis to breast detected by fluorine-18-fluorodeoxyglucose PET. J. Nucl. Med., 34: 1571, 1993.
23. Dewan, N. A., Gupta, N. C., Redepenning, L. S., Phalen, J. J. and Frick, M. P.: Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest, 104: 997, 1993.
24. Minn, H., Kangas, L., Kellokumpu-Lehtinen, P., Klemi, P., Sipilä, H., Vuorinen, J., Harkonen, P. and Lähde, M.: Uptake of 2-fluoro-2-deoxy-D-[U-14C]-glucose during chemotherapy in murine Lewis lung tumor. Int. J. Rad. Appl. Instr., 19: 55, 1992.
25. Rege, S. D., Hoh, C. K., Glaspy, J. A., Aberte, D. R., Dahlbom, M., Razavi, M. K., Phelps, M. E. and Hawkins, R. A.: Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. CA, 72: 82, 1993.
26. Slosman, D. O., Spiliopoulos, A., Couson, F., Nicod, L., Louis, O., Lemoine, R., Donater, A. and Junod, A. F.: Satellite PET and lung cancer: a prospective study in surgical patients. Nuc. Med. Comm., 14: 955, 1993.
27. Minn, H., Joensuu, H., Ahonen, A. and Klemi, P.: Fluorodeoxyglucose imaging: A method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. CA, 61: 1776, 1988.
28. Minn, H., Paul, R. and Ahonen, A.: Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J. Nucl. Med., 29: 1521, 1988.
29. Haberkorn, U., Strauss, L. G., Reisser, C., Haag, D., Dimitrakopoulo, A., Ziegler, S., Oberdorfer, F., Rudat, V. and Van Kaick, G.: Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J. Nucl. Med., 32: 1548, 1991.
30. Bailet, J. W., Abemayor, E., Jabour, B. A., Hawkins, R. A., Ho, C. and Ward, P. H.: Positron emission tomography: a new precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope, 102: 281, 1992.
31. Rege, S. D., Chaiken, L., Hoh, C. K., Choi, Y., Lufkin, R., Anzai, Y., Juillard, G., Maddahi, J., Phelps, M. E. and Hawkins, R. A.: Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with PET. Radiology, 189: 807, 1993.
32. Lindholm, P., Leskinen-Kallio, S., Minn, H., Bergman, J., Haaparanta, M., Lehikoinen, P., Nagren, K., Ruotsabinen, U., Teräs, M. and Joensuu, H.: Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer. J. Nucl. Med., 34: 1711, 1993.
33. Reisser, C., Haberkorn, U. and Strauss, L. G.: The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors. J. Otolaryng., 22: 231, 1993.
34. Haberkorn, U., Strauss, L. G., Dimitrakopoulou, A., Seiffert, E., Oberdorfer, F., Ziegler, S., Reisser, C., Doll, J., Helus, F. and Van Kaick, G.: Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J. Nucl. Med., 34: 12, 1993.
35. Jabour, B. A., Choi, Y., Hoh, C. K., Rege, S. D., Soong, J. C., Lufkin, R. B., Hanafee, W. N., Maddahi, J., Chaiken, L. and Bailet, J.: Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology, 186: 27, 1993.
36. Yonekura, Y., Benua, R. S., Brill, A. B., Som, P., Yeh, S. D., Kemeny, S. D., Fowler, J. S., MacGregor, R. R., Stamm, R., Christmas, D. R. and Wolf, A. P.: Increased accumulation of 2-Deoxy-2[18F]Fluoro-D-glucose in liver metastases from colon carcinoma. J. Nucl. Med., 23: 1133, 1982.
37. Strauss, L. G., Clorius, J. H., Schlag, P., Lehner, B., Kimmig, B., Engenhart, R., Marin-Grez, M., Helus, F., Oberdorfer, F. and Schmidlin, P.: Recurrence of colorectal tumors: PET evaluation. Radiology, 170: 329, 1989.
38. Gupta, N. C., Falk, P. M., Frank, A. L., Thorson, A. M., Frick, M. P. and Bowman, B.: Pre-operative staging of colorectal carcinoma using positron emission tomography. Nebraska Med. J., 78: 30, 1993.
39. Goldberg, M. A., Lee, M. J., Fischman, A. J., Mueller, P. R., Alpert, N. M. and Thrall, J. H.: Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: potential role in oncologic imaging. Radiographics, 13: 1047, 1993.
40. Schiepers, C., Penninck, F., De Vadder, N., Merck, E., Mortelmans, L., Bormans, G., Marchal, G., Filez, L. and Aerts, R.: Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur. J. Surg. Oncol., 21: 517, 1995.
41. Karlan, B. Y., Hawkins, R., Hoh, C., Leem, Tsen, Cane, P. and Glaspy, J.: Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynec. Oncol., 51: 175, 1993.
42. Kern, K. A., Brunetti, A., Norton, J. A., Chang, A. E, Malawer, M., Lack, E., Finn, R. D., Rosenberg, S. A. and Larson, S. M.: Metabolic imaging of human extremity musculoskeletal tumors by PET. J. Nucl. Med., 29: 181, 1988.
43. Adler, L. P., Blair, H. F., Makley, J. T., Williams, R. P., Joyce, M. J., Leisure, G., Al-Kaisi, N. and Miraldi, F.: Noninvasive grading of musculoskeletal tumors using PET. J. Nucl. Med., 32: 1508, 1991.
44. Nitzsche, E. U., Choi, Y., Killion, D., Hoh, C. K., Hawkins, R. A., Rosenthal, J. T., Buxton, D. B., Huang, S. C., Phelps, M. E. and Schelbert, H. R.: Quantification and parametric imaging of renal cortical blood flow in vivo based on patlak graphical analysis. Kidney Int., 44: 985, 1993.
45. Sokoloff, L., Reivich, M., Kennedy, C., Des Rosiers, M. H., Patlak, C. S., Pettigrew, K. D., Sakurada, O. and Shinohara, M.: The [14C]-deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem., 28: 897, 1977.
46. Huang, S. C., Phelps, M. E., Hoffman, E. J., Sideris, K., Selin, C. J. and Kuhl, D. E.: Noninvasive determination of local cerebral metabolic rate of glucose in man. Amer. J. Physiol., 238: E69, 1980.
47. Patlak, C. S., Blasberg, R. G. and Fenstermacher, J. D.: Graphical evaluation of blood to brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab., 3: 1, 1983.
48. Patlak, C. S. and Blasberg, R. G.: Graphical evaluation of blood to brain transfer constants from multiple time uptake data. Generalizations. J. Cereb. Blood Flow Metab., 5: 584, 1985.
49. Kim, C. K., Gupta, N. C., Chandramouli, B. and Alavi, A.: Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J. Nucl. Med., 35: 164, 1994.
50. Zasadny, K. R. and Wahl, R. L.: Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology, 189: 847, 1993.
51. Lindholm, P., Minn, H., Leskinen-Kallio, S., Bergman, J., Ruotsalainen, U. and Joesuu, H.: Influence of the blood glucose concentration on FDG uptake in cancer - a PET study. J. Nucl. Med., 34: 1, 1993.
52. Knuuti, M. J., Nuutila, P., Ruotsalainen, U., Saraste, M., Härkönen, R., Ahonen, A., Teräs, M., Haaparanta, M., Wegelius, U. and Haapanen, A.: Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. J. Nucl. Med., 33: 1255, 1992.
53. Brown, R. S. and Wahl, R. L.: Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. CA, 72: 2979, 1993.
54. Wahl, R. L., Henry, C. A. and Ethier, S. P.: Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology, 183: 643, 1992.
55. Langen, K. J., Braun, U., Rota Kops, E., Herzog, H., Kuwert, T., Nebeling, B. and Feinendegen, L. E.: The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J. Nucl. Med., 34: 355, 1993.
56. Minn, H., Leskinen-Kallio, S., Lindholm, P., Bergman, J., Ruotsalainen, U., Teräs, M. and Haaparanta, M.: [18F]fluorodeoxyglucose uptake in tumors: kinetic vs. steady-state methods with reference to plasma insulin. J. Comput. Assist. Tomogr., 17: 115, 1993.
57. Hoffman, E. J. and Phelps, M. E.: Positron emission tomography: principles and quantitation. In: Positron Emission Tomography and Autoradiography. Principles and Applications for the Brain and Heart. Edited by M. E. Phelps, J. C. Mazziotta and H. R. Schelbert. New York: Raven Press, chapt. 6, pp. 237-284, 1986.
58. Neelin, P., Crossman, J., Hawkes, D. J., Ma, Y. and Evans, A. C.: Validation of an MRI/PET landmark registration method using 3D simulated PET images and point simulations. Comput. Med. Imag. Graphics, 17: 351, 1993.
59. Turkington, T. G., Jaszczak, R. J., Pelizzari, C. A., Harris, C. C., MacFall, J. R., Hoffman, J. M. and Coleman, R. E.: Accuracy of registration of PET, SPECT and MR images of a brain phantom. J. Nucl. Med., 34: 1587, 1993.
60. Woods, R. P., Mazziotta, J. C. and Cherry, S. R.: MRI-PET registration with automated algorithm. J. Comput. Assist. Tomogr., 17: 536, 1993.
61. Kapouleas, I., Alavi, A., Alves, W. M., Gur, W. E. and Weiss, D. W.: Registration of three-dimensional MR and PET images of the human brain without markers. Radiology, 181: 731, 1991.
62. Hoh, C. K., Dahlbom, M., Harris, G. C., Choi, Y., Hawkins, R. A., Phelps, M. E. and Maddahi, J.: Automated iterative three-dimensional registration of positron emission tomography images. J. Nucl. Med., 34: 2009, 1993.
63. Bacharach, S. L., Douglas, M. A., Carson, R. E., Kalkowski, P. J., Freedman, N. M., Perroni-Filardi, P. and Bonow, R. O.: Three-dimensional registration of cardiac positron emission tomography attenuation scans. J. Nucl. Med., 34: 311, 1993.
64. Wahl, R. L., Quint, L. E., Cieslak, R. D., Aisen, A. M., Koeppe, R. A. and Meyer, C. R.: "Anatometabolic" tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity. J. Nucl. Med., 34: 1190, 1993.
65. Di Chiro, G., Brooks, R. A. and Sokoloff, L.: Glycolytic rate and histological grade of human cerebral gliomas: a study with 18F-fluorodeoxyglucose and positron emission tomography. In: Positron Emission Tomography of the Brain. Edited by W. D. Heiss and M. D. Phelps. New York: Springer-Verlag, pp. 181-191, 1983.
66. Di Chiro, G., DeLaPaz, R. L., Brooks, R. A., Sokoloff, L., Kornblith, P. L., Smith, B. H., Patronas, N. J., Kufta, C. V., Kessler, R. M., Johnston, G. S. et al: Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and position emission tomography. Neurology, 32: 1323, 1982.
67. Di Chiro, G., Hatazawa, J., Katz, D. A., Rizzoli, H. V. and De Michele, D.: Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology, 164: 521, 1987.
68. Di Chiro, G., Oldfield, E., Wright, D. C., De Michele, D., Katz, D. A., Patronas, N. J., Doppman, J. L., Larson, S. M., Ito, M. and Kufta, C. V.: Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR, 150: 189, 1988.
69. Di Chiro, G.: Positron emission tomography using [18F]fluoro-deoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest. Radiol., 22: 360, 1987.
70. Alavi, J. B., Alavi, A., Chawluk, J., Kushner, M., Powe, J., Hickey, W. and Reivich, M.: Positron emission tomography in patients with glioma - a predictor of prognosis. CA, 62: 1074, 1988.
71. Patronas, N., di Chiro, G., Kufta, C., Bairamian, D., Kornblith, P. L., Simon, R. and Larson, S. M.: Prediction of survival in glioma patients by means of positron emission tomography. J. Neurosurg., 62: 816, 1985.
72. Snead, O. C. 3rd, Chen, L. S., Mitchell, W. G., Kongelbeck, S. R., Raffel, C., Gilles, F. H. and Nelson, M. D. Jr.: Usefulness of [18F]fluorodeoxyglucose positron emission tomography in pediatric epilepsy surgery. Ped. Neurol., 14: 98, 1996.
73. Cummings, T. J., Chugani, D. C. and Chugani, H. T.: Positron emission tomography in pediatric epilepsy. Neurosurg. Clin. N. Amer., 6: 465, 1995.
74. Chugani, H. T.: The role of PET in childhood epilepsy. J. Child Neurol., 9: S82, 1994.
75. Cook, M. J. and Kilpatrick, C.: Imaging in epilepsy. Curr. Opin. Neurol., 7: 123, 1994.
76. Chugani, H. T.: PET in preoperative evaluation of intractable epilepsy. Ped. Neurol., 9: 411, 1993.
77. Chugani, H. T.: The use of positron emission tomography in the clinical assessment of epilepsy. Sem. Nucl. Med., 22: 247, 1992.
78. Di Carli, M. F., Asgarzadie, F., Schelbert, H. R., Brunken, R. C., Laks, H., Phelps, M. E. and Maddahi, J.: Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation, 92: 3436, 1995.
79. Grandin, C., Wijns, W., Melin, J. A., Bol, A., Robert, A. R., Heyndrick, G. R., Michel, C. and Vanoverschelde, J. L.: Delineation of myocardial viability with PET. J. Nucl. Med., 36: 1543, 1995.
80. Jain, D. and Zaret, B. L.: Nuclear imaging techniques for the assessment of myocardial viability. Cardiol. Clin., 13: 43, 1995.
81. Schelbert, H. R.: Metabolic imaging to assess myocardial viability. J. Nucl. Med., 35: 8S, 1994.
82. Hawkins, R. A., Hoh, C. K., Glaspy, J. A., Choi, Y., Dahlbom, M., Rege, S., Messa, C., Neitszche, E., Hoffman, E., Seeger, L., Maddahi, J. and Phelps, M. E.: The role of positron emission tomography in oncology and other whole-body applications. Sem. Nucl. Med., 22: 268, 1992.
83. Effert, P. J., Bares, R., Handt, S., Wolff, J. M., Bull, U. and Jakse, G.: Metabolic imaging of untreated prostate cancer by positron emission tomography with 18F-fluorine-labeled deoxyglucose. J. Urol., 155: 994, 1996.
84. Shreve, P. D., Grossman, H. B., Gross, M. D. and Wahl, R. L.: Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology, 199: 751, 1996.
85. Laubenbacher, C., Hofer, C., Avril, N., Block, T., Ziegler, S., Herz, M., Kruschke, C., Hartung, R. and Schwaiger, M.: F-18 FDG PET for differentiation of local recurrent prostate cancer and scar. J. Nucl. Med., suppl., 36: 198P, 1995.
86. Yeh, S. D. J., Imbriaco, M., Garza, D., Kalaigian, H., Reddy, D., Zhang, J. J., Horowitz, S., Finn, R., Goldsmith, S. J., Scher, H. and Larson, S. M.: Twenty percent of bony metastases of hormone resistant prostate cancer are detected by PETFDG whole body scanning. J. Nucl. Med., suppl., 36: 198P, 1995.
87. Hoh, C. K., Rosen, P. J., Belldegrun, A., Moon, D. H., Maddahi, J. and Phelps, M. E.: Quantitative and whole body FDG PET in the evaluation of suramin therapy in patients with metastatic prostate cancer. J. Nucl. Med., suppl., 37: 267P, 1996.
88. Bachor, R., Kotzerke, J., Gottfried, H. W., Brandle, E., Reske, S. N. and Hautmann, R.: Positron emission tomography in diagnosis of renal cell carcinoma. Urologe, 35: 146, 1996.
89. Miyauchi, T., Brown, R. S., Grossman, H. B., Wojno, K. and Wahl, R. L.: Correlation between visualization of primary renal cancer by FDG-PET and histopathological findings. J. Nucl. Med., suppl., 37: 64P, 1996.
90. Hoh, C. K., Figlin, R. A., Belldegrun, A., Moon, D. H., Franklin, J., Phelps, M. E. and Maddahi, J.: Evaluation of renal cell carcinoma with whole body FDG PET. J. Nucl. Med., 37: 141P, 1996.
91. Franklin, J., Hoh, C., Gitlitz, B., Phelps, M., Figlin, R. and Belldegrun, A.: Positron emission tomography (PET) scan for imaging of advanced renal cell carcinoma (RCC). J. Urol., part 2, 155: 581A, abstract 1083, 1996.
92. Harns, W., Bares, R., Kamps, H., Gronimus, R., Boeckmann, W., Jakse, G. and Büll, U.: Therapy control of metastatic testicular carcinoma with F18-DOG PET. J. Nucl. Med., suppl., 36: 198P, 1995.
93. Stephens, A. W., Gonin, R., Hutchins, G. D. and Einhorn, L. H.: Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J. Clin. Oncol., 14: 1637, 1996.
94. Wilson, C. B., Young, H. E., Ott, R. J., Flower, M. A., Cronin, B. F., Pratt, B. E., McCready, V. R. and Horwich, A.: Imaging metastatic testicular germ cell tumours with 18 FDG positron emission tomography: prospects for detection and management. Eur. J. Nucl. Med., 22: 508, 1995.
95. Inaba, T., Yamashita, M., Kawase, Y., Nakahashi, H. and Watanabe, H.: Quantitative measurement of renal plasma flow by positron emission tomography with oxygen-15 water. Tohoku J. Exp. Med., 159: 283, 1989.
96. Killion, D., Nitsche, E., Choi, Y., Schelbert, H. and Rosenthal, J. T.: Positron emission tomography: a new method for determination of renal function. J. Urol., 150: 1064, 1993.
97. Alauddin, M. M., Conti, P. S., Lever, J. R., Mazza, S. M. and Hamzeh, F. M.: Synthesis of F-18 9-[(3-fluoro-1-hydroxy-2-propoxy)-methyl]-guanine (FHPG) for in vivo imaging of viral infection and gene therapy with PET. J. Nucl. Med., suppl., 37: 193P, 1996.
98. Goldman, S., Monclus, M., Cool, V., Damhaut, P., Luxen, A., Levivier, M., Brotchi, J., Hildebrand, J. and Velu, T.: A novel PET tracer for evaluation of gene therapy. J. Nucl. Med., suppl., 37: 53P, 1996.
99. Barrio, J. R., Namavari, M., Satyamurthy, N., Srinivasan, A., Herschman, H., Gambhir, S., Cherry, S. and Phelps, M. E.: 8-[F-18]fluoroacyclovir: an in-vivo probe for gene expression with PET. J. Nucl. Med., suppl., 37: 193P, 1996.
100. deKernion, J. B., Ramming, K. P. and Smith, R. B.: The natural history of metastatic renal cell carcinoma: a computer analysis. J. Urol., 120: 148, 1978.
101. Richie, J. P., Garnick, M. B. and Finberg, H.: Computerized tomography: how accurate for abdominal staging of testis tumors? J. Urol., 127: 715, 1982.
102. McLeod, D. G., Weiss, R. I. B., Stablein, D. M., Muggia, F. M., Paulson, D. F., Ellis, J. H., Spaulding, J. T. and Donohue, J. P.: Staging relationships and outcome in early stage testicular cancer: A report from the Testicular Cancer Intergroup Study. J. Urol., 145: 1178, 1991.